Please assess the completion status of the following clinical trial:

Trial Title: Study of Platinum Plus Etoposide With or Without BGB-A317 in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Age≥18 years old, male or female, signed Informed Consent Form (ICF).~2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~3. Histologically or cytologically confirmed ES-SCLC~4. No prior systemic treatment for ES-SCLC~5. Adequate hematologic and end organ function~Key Exclusion Criteria:~1. Active leptomeningeal disease or uncontrolled, untreated brain metastasis;~2. Prior therapy with an antibody or drug against immune checkpoint pathways, including but not limited to, anti program death receptor-1 (anti-PD-1), anti-PD-L1, or anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA-4) antibody;~3. Was administered a live vaccine ≤ 4 weeks before randomization;~4. Active autoimmune diseases or history of autoimmune diseases that may relapse~5. Any condition that required systemic treatment with either corticosteroids or other immunosuppressive medication ≤ 14 days before randomization;~6. With a history of interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases;~7. Severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy within 2 weeks prior to randomization, including but not limited to tuberculosis infection;~8. Participant with untreated hepatitis B virus (HBV)/hepatitis C virus (HCV), or a known history of HIV infection;~9. Participants with toxicities (as a result of prior anticancer therapy) which have not recovered to baseline or stabilized at the time of randomization;~10. Clinically significant pericardial effusion, or Clinically uncontrolled pleural effusion~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tislelizumab plus etoposide and platinum (Type: EXPERIMENTAL): None
- Placebo plus etoposide and platinum (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).